[1]申辽辽,高艳菊.胃癌合并肝硬化行腹腔镜胃癌根治术对患者免疫功能的影响[J].陕西医学杂志,2021,50(5):590-593.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.019]
　SHEN Liaoliao,GAO Yanju.Influence of laparoscopic radical gastric cancer resection on immune function in patients with gastric cancer and liver cirrhosis[J].,2021,50(5):590-593.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.019]
点击复制

胃癌合并肝硬化行腹腔镜胃癌根治术对患者免疫功能的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年5期
页码:
590-593
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Influence of laparoscopic radical gastric cancer resection on immune function in patients with gastric cancer and liver cirrhosis
作者:
申辽辽; 高艳菊
(榆林市第二医院检验科,陕西 榆林 719000)
Author(s):
SHEN Liaoliao; GAO Yanju
(Department of Laboratory Medicine,Yulin No.2 Hospital,Yulin 719000,China)
关键词:
胃癌;  肝硬化;  腹腔镜胃癌根治术;  免疫功能;  肿瘤标志物;  并发症
Keywords:
Gastric cancer;  Liver cirrhosis;  Laparoscopic radical gastric cancer resection;  Immune function;  Tumor marker;  Complication
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7377.2021.05.019
文献标志码:
A
摘要:
目的:探讨胃癌合并肝硬化患者行腹腔镜胃癌根治术对患者免疫功能的影响。方法:选择胃癌合并肝硬化患者72例,根据随机信封抽签原则分为腹腔镜组与对照组各36例。对照组采用传统开腹胃癌根治术治疗,腹腔镜组采用腹腔镜胃癌根治术治疗,检测两组患者免疫功能的变化情况,观察与随访患者的预后。结果:两组手术时间、淋巴结清扫数目对比差异均无统计学意义(均P>0.05),腹腔镜组的术中出血量、术后胃肠道恢复时间、术后拔除胃管时间、术后住院时间均少于对照组(均P<0.05)。腹腔镜组术后7 d的发热、出血、吻合口漏、肠梗阻、胃瘫等并发症发生率为8.3%,低于对照组的33.3%(P<0.05)。腹腔镜组与对照组术后7 d的血清高尔基体跨膜糖蛋白73(GP73)、甲胎蛋白L3(AFP-L3)均低于术前1 d(均P<0.05),腹腔镜组均低于对照组(均P<0.05)。两组术后7 d的CD4+T细胞比例高于术前1 d(P<0.05),腹腔镜组高于对照组(P<0.05),两组手术前后CD3+T细胞比例对比差异无统计学意义(P>0.05)。随访到2021年1月,腹腔镜组复发率为5.6%,低于对照组的22.2%(P<0.05)。结论:胃癌合并肝硬化患者行腹腔镜胃癌根治术能促进机体免疫功能的恢复,抑制肝功能标志物的表达,减少对患者的创伤与并发症的发生,从而促进患者康复,降低复发率。
Abstract:
Objective:To investigate the influence of laparoscopic radical gastric cancer resection on immune function in patients with gastric cancer and liver cirrhosis.Methods:72 cases of patients with gastric cancer and liver cirrhosis were selected and divided into laparoscopic group and control group with 36 cases in each groups.The control group was treated with traditional laparotomy radical gastric cancer,and the laparoscopic group was treated with laparoscopic radical gastric cancer.The changes in the immune function of the patients were measured.Results:There were no significant differences in the operation time and the number of lymph node dissection between the two groups(all P>0.05).The intraoperative blood loss,postoperative gastrointestinal recovery time,postoperative gastric tube removal time,postoperative hospital stay in the laparoscopic group were less than those in the control group(all P<0.05).The incidence of complications such as fever,bleeding,anastomotic leakage,intestinal obstruction,and gastroparesis in the laparoscopic group at 7 days after operation were 8.3%,which were lower than 33.3% in the control group(P<0.05).The serum Golgi transmembrane glycoprotein 73(GP73)and alpha-fetal protein L3(AFP-L3)in the laparoscopic group and the control group at 7 days after operation were lower than that of the preoperative 1 day,and the laparoscopic group were lower than the control group(all P<0.05).The ratio of CD4+T cells in the two groups at 7 days after operation were higher than that in the 1 day before operation,and the laparoscopic group were higher than that in the control group(all P<0.05).There were no significant differences in the ratio of CD3+ T cells before and after operation between the two groups(all P>0.05).Followed-up until January 2021,the recurrence rate in the laparoscopic group was 5.6%,which was lower than 22.2% in the control group(P<0.05).Conclusion:Laparoscopic laparoscopic radical gastric cancer resection for patients with gastric cancer and liver cirrhosis can promote the recovery of immune function,inhibit the expression of liver function markers,reduce the occurrence of trauma and complications,and promote the recovery of the patient,reduce the recurrence rate.

参考文献/References:

[1] 马 婷,王品昊,朱 婕,等.行健汤联合穴位贴敷治疗进展期胃癌癌因性疲乏疗效及对患者免疫功能的影响[J].陕西中医,2020,41(10):1410-1413.
[2] 庞芳宁,白 槟,杨 鹏,等.不同部位原发性胃癌临床病理特征对比研究[J].陕西医学杂志,2020,49(5):626-629.
[3] 杨 鹏,庞芳宁,白 槟,等.胃癌淋巴结清扫数目与预后关系探讨[J].陕西医学杂志,2020,49(8):987-990.
[4] 李国新,刘 浩.胃癌微创外科临床研究进展及展望(2000-2020)[J].中国实用外科杂志,2020,40(1):62-64,69.
[5] 谷军保,鲍学斌,马 钊.腹腔镜胃癌根治术对患者免疫功能凝血功能及预后的影响[J].中华肿瘤杂志,2020,42(7):598-602.
[6] 徐泽宽,王林俊,李博文.腹腔镜胃癌手术进展及展望[J].中国实用外科杂志,2020,40(2):185-190.
[7] Shao L,Pang N,Yan P,et al.Control of body temperature and immune function in patients undergoing open surgery for gastric cancer[J].Bosn J Basic Med Sci,2018,18(3):289-296.
[8] Sunakawa Y,Inoue E,Matoba R,et al.DELIVER(JACCRO GC-08)trial:Discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer[J].Future Oncol,2019,15(21):2441-2447.
[9] 祝和攀,陈鸣宇,潘军海,等.胃癌伴肝硬化患者行腹腔镜胃癌根治术的安全性及可行性[J].中华胃肠外科杂志,2020,23(10):998-1002.
[10] 刘晓东,曹守根,周岩冰.加速康复外科路径在全腹腔镜远端胃癌根治术围手术期中的应用[J].中华普通外科杂志,2020,35(2):152-153.
[11] Vrana D,Matzenauer M,Neoral C,et al.From tumor immunology to immunotherapy in gastric and esophageal cancer[J].Int J Mol Sci,2018,20(1):99-014.
[12] Zhang J,Si X,Li W,et al.Effect of peripherally inserted central catheter(PICC)parenteral nutrition on immune function and nutritional support after radical gastrectomy for gastric cancer[J].Pak J Pharm Sci,2019,32(3):1441-1445.
[13] 朱纯超,赵 刚.腹腔镜-内镜联合局部胃切除治疗早期胃癌[J].中华胃肠外科杂志,2020,23(10):939-943.
[14] 刘 昊,徐 泉,马福海,等.全腹腔镜胃部分离断后胃肠吻合术治疗胃癌合并幽门梗阻的临床效果[J].中华肿瘤杂志,2020,42(6):445-448.
[15] Botwe G,He H,Zhiyu S,et al.Effects of post-surgical parenteral nutrition on patients with gastric cancer[J].World J Surg Oncol,2018,49(4):1320-1328.
[16] Cheng Y,Zhang J,Zhang L,et al.Enteral immunonutrition versus enteral nutrition for gastric cancer patients undergoing a total gastrectomy:A systematic review and meta-analysis[J].BMC Gastroenterol,2018,18(1):11.
[17] 徐志远,杜义安,胡 灿,等.十二指肠非离断式前入路胰腺上区淋巴结清扫在腹腔镜胃癌根治术中的可行性分析[J].中华胃肠外科杂志,2020,23(1):76-78.
[18] 田庆林,李 阳,陈晓峰.腹腔镜远端胃癌根治术毕Ⅱ式联合Braun吻合术对胃癌肠道屏障功能血清炎性因子水平的影响[J].河北医学,2020,26(1):41-45.
[19] Kim TS,Silva E,Coit DG,et al.Intratumoral immune response to gastric cancer varies by molecular and histologic subtype[J].Gut,2019,43(6):851-860.
[20] Li W,Zhang X,Wu F,et al.Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer[J].Cell Death Dis,2019,10(12):918.

相似文献/References:

[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
　HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(5):121.
[2]唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究*[J].陕西医学杂志,2019,(4):435.
　TANG Yarong..Clinical effect analysis of combined therapy with tiago and hyperthermia in the treatment of malignant ascites in elderly patients with gastric cancer[J].,2019,(5):435.
[3]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
　LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(5):456.
[4]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[5]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
　MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(5):679.
[6]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
　SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(5):958.
[7]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010.
　GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(5):1010.
[8]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
　KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(5):1115.
[9]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[10]刘小莹,郑宏波,王山军△,等.恩替卡韦单药方案维持对初始行拉米夫定+阿德福韦酯方案治疗慢性乙型肝炎及慢性乙型肝炎后肝硬化疗效影响[J].陕西医学杂志,2020,49(3):381.
　LIUXiaoying,ZHENG Hongbo,WANG Shanjun,et al.Influence of maintenance of ETVmonotherapy regimen on clinical efficacy of initial LAM+ADV regimen of patients with CHB and post-CHB cirrhosis[J].,2020,49(5):381.

备注/Memo

备注/Memo:
基金项目:陕西省科技厅科技攻关项目(2018KS-14-03)
更新日期/Last Update: 2021-05-06